CELL INTELLIGENCE · 肿瘤细胞治疗研究

为体弱和老年骨髓瘤患者定制治疗

Tailoring Therapy for Frail and Elderly Myeloma Patients.

多发性骨髓瘤是一种浆细胞恶性肿瘤，其临床结局具有异质性。

Arlocabtagene autoleucel：一种用于重度预治疗复发/难治性多发性骨髓瘤的靶向 GPRC5D CAR-T 细胞疗法

Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

多发性骨髓瘤中的单特异性和双特异性嵌合抗原受体（CAR）T 细胞治疗：系统综述、荟萃分析与荟萃回归

Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression

多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸

Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.

探索 BCMA/GPRC5D 后的治疗格局：塞利尼索、硼替佐米与地塞米松在五重难治性多发性骨髓瘤序贯免疫治疗失败后的疗效——多中心分析

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refrac

动态可靶向细胞外囊泡表面蛋白监测 CAR-T 治疗的缓解深度

Dynamic Targetable Extracellular Vesicle Surface Proteins Monitor Depth of Response to CAR T Therapy.

ide-cel 早期复发后 BCMA 靶向双特异性抗体治疗结局不佳：一项法国真实世界研究

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

双特异性抗体在多发性骨髓瘤中的演进

The evolution of bispecific antibodies in multiple myeloma.

靶向 GPRC5D 的 CAR-T 细胞治疗复发/难治性多发性骨髓瘤：病例报告与文献综述

Targeting GPRC5D With CAR-T Cells in Relapse/Refractory Multiple Myeloma: Case Report and Literature Review.

无限可能以及如何利用它们？最佳治疗顺序是什么？

Endless possibilities and how to exploit them? What is the optimal treatment sequence?